Product Information
QC MIGRAINE 250-250-65 MG CPLT is a generic product labeled by Chain Drug Marketing Association, priced at $0.0672 per EA under NDC 83324009924. Its NADAC has been published 69 times since Jan 29, 2025.
FDA first approved this application on Feb 23, 2021.
Strength
250; 250; 65 mg/1; mg/1; mg/1
Manufacturer
Chain Drug Marketing AssociationNDC
83324009924
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
ACETAMINOPHEN; ASPIRIN; CAFFEINEApproval Type
Generic (ANDA)
FDA Application
ANDA214039FDA Approved
2/23/2021
On Market Since
5/1/2024
Pharmacological Classes
Price Statistics
The NADAC for QC MIGRAINE 250-250-65 MG CPLT has been published 69 times since Jan 29, 2025, and over the history we have for it it has risen 6.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0672 per EA |
|---|---|
| All-time high | $0.0691 (Oct 15, 2025) |
| All-time low | $0.0628 (Jan 29, 2025) |
| 52-week high | $0.0691 |
| 52-week low | $0.0635 |
| Median price | $0.0656 |
| Average price | $0.0657 |
| Largest weekly change | +5.5% (Apr 23, 2025) |
| Weeks tracked | 69 |
| Tracking since | Jan 29, 2025 |
1W
N/A
1M
N/A
3M
N/A
6M
+2.1%
1Y
-2.8%
3Y
N/A
5Y
N/A
All
+6.9%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ACETAMINOPHEN, ASPIRIN and CAFFEINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chain Drug Marketing Association manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ACETAMINOPHEN, ASPIRIN and CAFFEINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QC MIGRAINE 250-250-65 MG CPLT?
The current National Average Drug Acquisition Cost (NADAC) for QC MIGRAINE 250-250-65 MG CPLT, manufactured by Chain Drug Marketing Association, is $0.0672 per EA (NDC 83324009924), effective May 20, 2026.
How has the price of QC MIGRAINE 250-250-65 MG CPLT changed over time?
Over the history we have for it, the NADAC for QC MIGRAINE 250-250-65 MG CPLT has risen 6.9%. It has been tracked across 69 weekly CMS publications since Jan 29, 2025.
What are the highest and lowest recorded NADAC prices for QC MIGRAINE 250-250-65 MG CPLT?
Since Jan 29, 2025, the NADAC for QC MIGRAINE 250-250-65 MG CPLT has ranged from a low of $0.0628 (Jan 29, 2025) to a high of $0.0691 (Oct 15, 2025), with a median of $0.0656 per EA.
Are there cheaper alternatives to QC MIGRAINE 250-250-65 MG CPLT?
No other NADAC-published product currently shares the active ingredient and strength of QC MIGRAINE 250-250-65 MG CPLT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures QC MIGRAINE 250-250-65 MG CPLT?
QC MIGRAINE 250-250-65 MG CPLT (NDC 83324009924) is labeled by Chain Drug Marketing Association, and CMS classifies it as a generic product.